Investigational drug · Phase 2
IW-6463
Also called: CY6463, zagociguat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "IW-6463"
First trial start
2024
Sep 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IW-6463", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "IW-6463" as an intervention, largest first.
- A Study of IW-6463 in Healthy VolunteersPivotal-lookingCompleted
Tisento TherapeuticsIndustry
NCT03856827 · 110 participants · Start Feb 6, 2019 · Primary completion Oct 22, 2019
Drug: IW-6463; Matching Placebo · For: Other
Sites: Leiden, Netherlands
- Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable SchizophreniaCompleted
Tisento TherapeuticsIndustry
NCT04972227 · 48 participants · Start Sep 10, 2021 · Primary completion Apr 18, 2022
Drug: CY6463; Placebo · For: Schizophrenia
Sites: Long Beach, California; Marlton, New Jersey
Tisento TherapeuticsIndustry
NCT06402123 · 43 participants · Start Sep 10, 2024 · Primary completion Jun 29, 2026
Drug: zagociguat 15mg; zagociguat 30mg and 1 more · For: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Sites: La Jolla, California; Aurora, Colorado; Atlanta, Georgia · 20 sites in all
Tisento TherapeuticsIndustry
NCT06961344 · 37 participants · Start Aug 18, 2025 · Primary completion Oct 29, 2026
Drug: zagociguat 15mg · For: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Sites: La Jolla, California; Aurora, Colorado; Atlanta, Georgia · 16 sites in all
Tisento TherapeuticsIndustry
NCT04240158 · 24 participants · Start Jan 6, 2020 · Primary completion May 22, 2020
Drug: IW-6463; Matching Placebo · For: Other
Sites: Leiden, Netherlands
- A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular PathologyTerminated
Tisento TherapeuticsIndustry
NCT04798989 · 12 participants · Start Nov 2, 2021 · Primary completion Nov 28, 2022
Drug: CY6463; Placebo · For: Alzheimer's Disease With Vascular Pathology
Sites: Scottsdale, Arizona; Miami, Florida; Honolulu, Hawaii · 5 sites in all
Tisento TherapeuticsIndustry
NCT04475549 · 8 participants · Start Nov 13, 2020 · Primary completion Jan 23, 2022
Drug: IW-6463 Tablets · For: MELAS
Sites: Washington D.C., District of Columbia; Baltimore, Maryland; Boston, Massachusetts · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies.
Chu KY · Intractable Rare Dis Res 2026
- Zagociguat prevented stressor-induced neuromuscular dysfunction, improved mitochondrial physiology, and increased exercise capacity in diverse mitochondrial respiratory chain disease zebrafish models.
Burg L, Yoon H, Peng M, et al. · Front Pharmacol 2025
- Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
van Kraaij SJW, Borghans L, Klaassen ES, et al. · Br J Clin Pharmacol 2023
- First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator.
van Kraaij SJW, Gal P, Borghans LGJM, et al. · Clin Transl Sci 2023
- The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.
Correia SS, Iyengar RR, Germano P, et al. · Front Pharmacol 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.